FDA approves Ocaliva for rare, chronic liver disease - FDA Press Releases

Today the U.S. Food and Drug Administration granted accelerated approval for Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as a single therapy in adults unable to tolerate UDCA.

from Food and Drug Administration--Press Releases http://ift.tt/25wFec9
via IFTTT